
Alteogen’s breakout Q1 overshadowed by US scrutiny of subcutaneous drug combos
Alteogen shattered its own sales record in the first quarter of 2025, riding a $45 million upfront payment from AstraZeneca and a surge in ALT-B4 product sales. Still, investors pulled back, as new U.S. drug pricing rules threaten to narrow what qualifies …